← Back to the timeline

Timeline › Low-rate stagnation

FDA approves semaglutide (Ozempic), a weekly GLP-1 drug; the first GLP-1 drug, exenatide, dates from 2005

5 December 2017 · Global (origin DNK) · Global level

Draft: not yet verifiedScience, invention & breakthrough technologyDemographics & society

Why it matters

The GLP-1 class moves from diabetes to obesity

Era
Low-rate stagnation (2013–19)
Track
Technology & science
Asset classes
Equities
Verify via
FDA
Wikipedia
Semaglutide (article on this event)
Date check
no date in Wikidata

Open in the interactive timeline, with its macro chartsSuggest a correction

Sources

References cited in the Wikipedia article, official and academic ones first.

Connected events

Events whose Wikipedia articles link to this one. Links show relatedness, not cause.

Previous and next events on the Technology & science track.

Cite this event

Wang, Y. (2026). FDA approves semaglutide (Ozempic), a weekly GLP-1 drug; the first GLP-1 drug, exenatide, dates from 2005 (5 December 2017). In Macro-financial history, 1900–2026, event E0448. https://macrofinancialhistory.com/event/e0448/

@misc{mefh_e0448,
  author = {Wang, Yuhui},
  title = {FDA approves semaglutide (Ozempic), a weekly GLP-1 drug; the first GLP-1 drug, exenatide, dates from 2005},
  howpublished = {Macro-financial history, 1900–2026, event E0448},
  year = {2026},
  url = {https://macrofinancialhistory.com/event/e0448/}
}